retatrutide triple agonist gip glp-1 glucagon phase 2 obesity 3: 28.7% Weight Loss (2026) Schematic illustration of monoagonists, dual

is approved for weight loss in adults and children ages 12 and over with obesity, and for adults with overweight plus at least one weight-related condition (such as type 2 diabetes or heart disease)

Focus on increasing daily movement through: Taking stairs instead of elevators Walking meetings when possible Parking farther away from destinations Incorporating movement breaks during work hours Nutrition Habits That Support Your Supplement Mindful Eating Practices Advanced BioNutritionals GLP-1 Plus helps you recognize satiety signals more clearly, making it easier to practice mindful eating

For more information: Ji ang Bian, PhD, MS, FACMI, can be reached at [email protected]

Keep the pen in an insulated travel case to maintain the correct temperature during transit